Veronique Michaud
Overview
Explore the profile of Veronique Michaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
741
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoon J, Schindler J, Loperfido M, Baricordi C, DeAndrade M, Jacobs M, et al.
Mol Ther
. 2024 Sep;
32(11):3847-3864.
PMID: 39295144
Pompe disease, a rare genetic neuromuscular disorder, is caused by a deficiency of acid alpha-glucosidase (GAA), leading to an accumulation of glycogen in lysosomes, and resulting in the progressive development...
2.
Klose M, Cristofoletti R, De Miranda Silva C, Mangal N, Turgeon J, Michaud V, et al.
Eur J Pharm Sci
. 2024 Jan;
194:106689.
PMID: 38171419
Oxycodone is one of the most commonly used opioids to treat moderate to severe pain. It is metabolized mainly by CYP3A4 and CYP2D6, while only a small fraction of the...
3.
Batt T, Herwig G, Annaheim S, Clement P, Furrer L, Hirsch C, et al.
Chimia (Aarau)
. 2023 Dec;
76(3):249-254.
PMID: 38069740
The COVID-19 pandemic resulted in shortages of personal protective equipment and medical devices in the initial phase. Agile small and medium-sized enterprises from regional textile industries reacted quickly. They delivered...
4.
SanFilippo S, Turgeon J, Michaud V, Nahass R, Brunetti L
Pharmacy (Basel)
. 2023 Nov;
11(6).
PMID: 37987392
Linezolid (LZD) has a longstanding reported association with the onset of serotonin toxicity (ST), secondary to drug-drug interactions with serotoninergic agents. There have been no conclusive data supporting the incidence...
5.
Jessop J, Russell J, DeJesus A, Bardolia C, Hanna A, Turgeon J, et al.
Am J Case Rep
. 2023 Feb;
24:e938850.
PMID: 36804920
BACKGROUND Comorbidities and polypharmacy are difficult to manage, as polypharmacy hinders identification and prevention of medication-related problems. Risk for adverse drug events (ADEs) can be minimized through pharmacogenomic (PGx) testing...
6.
Morales M, Maranon A, Hernandez C, Michaud V, Porras A
Polymers (Basel)
. 2023 Feb;
15(3).
PMID: 36771829
In the context of the preservation of natural resources, researchers show a growing interest in developing eco-friendly materials based on recycled polymers and natural fiber biocomposites to minimize plastic and...
7.
Dow P, Michaud V, Turgeon J
Clin Ther
. 2023 Jan;
45(2):99-105.
PMID: 36682993
A nonoptimized medication therapy (NOMT) event is an iatrogenic hazard or incident associated with medications and is a leading cause of death, serious injury, and illness. NOMT events are often...
8.
Russell J, Arwood M, Toro-Pagan N, Amin N, Cambridge M, Turgeon J, et al.
Medicina (Kaunas)
. 2023 Jan;
59(1).
PMID: 36676742
Pharmacotherapy for major depressive disorder (MDD) typically consists of trial-and-error and clinician preference approaches, where patients often fail one or more antidepressants before finding an optimal regimen. Pharmacogenomics (PGx) can...
9.
Vaucher J, Demongeot A, Michaud V, Leterrier Y
Polymers (Basel)
. 2022 Dec;
14(24).
PMID: 36559873
As part of a project that aims to provide people with disabilities with simple assistive devices in Colombia, the possibility of creating a PET filament that can be printed by...
10.
Pizzolato K, Thacker D, Del Toro-Pagan N, Amin N, Hanna A, Turgeon J, et al.
Pharmgenomics Pers Med
. 2022 Nov;
15:943-950.
PMID: 36393978
The opioid epidemic in the United States has exposed the need for providers to limit opioid dispensing and identify at-risk patients prior to prescribing opioids. With pharmacogenomic testing, clinicians can...